Literature DB >> 10331542

Interpretation of phenotype in genetically engineered mice.

T Doetschman1.   

Abstract

BACKGROUND AND
PURPOSE: In mice, genetic engineering involves two general approaches-addition of an exogenous gene, resulting in transgenic mice, and use of knockout mice, which have a targeted mutation of an endogenous gene. The advantages of these approaches is that questions can be asked about the function of a particular gene in a living mammalian organism, taking into account interactions among cells, tissues, and organs under normal, disease, injury, and stress situations.
METHODS: Review of the literature concentrating principally on knockout mice and questions of unexpected phenotypes, lack of phenotype, redundancy, and effect of genetic background on phenotype will be discussed.
CONCLUSION: There is little gene redundancy in mammals; knockout phenotypes exist even if none are immediately apparent; and investigating phenotypes in colonies of mixed genetic background may reveal not only more phenotypes, but also may lead to better understanding of the molecular or cellular mechanism underlying the phenotype and to discovery of modifier gene(s).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331542

Source DB:  PubMed          Journal:  Lab Anim Sci        ISSN: 0023-6764


  27 in total

Review 1.  Genotype to phenotype: challenges and opportunities.

Authors:  D P Holschneider; J C Shih
Journal:  Int J Dev Neurosci       Date:  2000-10       Impact factor: 2.457

2.  Manipulating the mouse genome: approaches and applications.

Authors:  F Sangiorgi
Journal:  J Nucl Cardiol       Date:  2001 Sep-Oct       Impact factor: 5.952

3.  Reduced mobility of fibroblast growth factor (FGF)-deficient myoblasts might contribute to dystrophic changes in the musculature of FGF2/FGF6/mdx triple-mutant mice.

Authors:  Petra Neuhaus; Svetlana Oustanina; Tomasz Loch; Marcus Krüger; Eva Bober; Rosanna Dono; Rolf Zeller; Thomas Braun
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

Review 4.  Cardiac-specific inducible and conditional gene targeting in mice.

Authors:  Thomas Doetschman; Mohamad Azhar
Journal:  Circ Res       Date:  2012-05-25       Impact factor: 17.367

Review 5.  Transforming growth factor beta signaling in adult cardiovascular diseases and repair.

Authors:  Thomas Doetschman; Joey V Barnett; Raymond B Runyan; Todd D Camenisch; Ronald L Heimark; Henk L Granzier; Simon J Conway; Mohamad Azhar
Journal:  Cell Tissue Res       Date:  2011-09-28       Impact factor: 5.249

6.  Molecular profiles of mitogen activated protein kinase signaling pathways in orofacial development.

Authors:  Saurabh Singh; Xiaolong Yin; M Michele Pisano; Robert M Greene
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2007-01

Review 7.  Probing human cardiovascular congenital disease using transgenic mouse models.

Authors:  Paige Snider; Simon J Conway
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

8.  Digital Microscopy, Image Analysis, and Virtual Slide Repository.

Authors:  Famke Aeffner; Hibret A Adissu; Michael C Boyle; Robert D Cardiff; Erik Hagendorn; Mark J Hoenerhoff; Robert Klopfleisch; Susan Newbigging; Dirk Schaudien; Oliver Turner; Kristin Wilson
Journal:  ILAR J       Date:  2018-12-01

9.  Sox17 haploinsufficiency results in perinatal biliary atresia and hepatitis in C57BL/6 background mice.

Authors:  Mami Uemura; Aisa Ozawa; Takumi Nagata; Kaoruko Kurasawa; Naoki Tsunekawa; Ikuo Nobuhisa; Tetsuya Taga; Kenshiro Hara; Akihiko Kudo; Hayato Kawakami; Yukio Saijoh; Masamichi Kurohmaru; Masami Kanai-Azuma; Yoshiakira Kanai
Journal:  Development       Date:  2013-02-01       Impact factor: 6.868

10.  A locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation, while an unlinked locus augments resistance of female mice.

Authors:  Patric Lundberg; Paula Welander; Harry Openshaw; Christina Nalbandian; Carl Edwards; Lyle Moldawer; Edouard Cantin
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.